Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Rating) by 2.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,990,815 shares of the biotechnology company’s stock after purchasing an additional 69,862 shares during the quarter. JPMorgan Chase & Co. owned 2.83% of Arrowhead Pharmaceuticals worth $105,306,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Arrowhead Pharmaceuticals by 1.2% in the first quarter. BlackRock Inc. now owns 12,155,084 shares of the biotechnology company’s stock valued at $559,014,000 after acquiring an additional 147,021 shares during the period. Vanguard Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 9,718,250 shares of the biotechnology company’s stock valued at $446,943,000 after acquiring an additional 78,107 shares during the period. State Street Corp lifted its holdings in Arrowhead Pharmaceuticals by 19.9% in the first quarter. State Street Corp now owns 4,681,955 shares of the biotechnology company’s stock valued at $215,323,000 after acquiring an additional 777,184 shares during the period. Invesco Ltd. lifted its holdings in Arrowhead Pharmaceuticals by 1.2% in the first quarter. Invesco Ltd. now owns 2,334,074 shares of the biotechnology company’s stock valued at $107,345,000 after acquiring an additional 28,433 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Arrowhead Pharmaceuticals by 3.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,085,723 shares of the biotechnology company’s stock valued at $49,933,000 after acquiring an additional 35,829 shares during the period. 67.29% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Down 1.0 %

Arrowhead Pharmaceuticals stock opened at $29.55 on Wednesday. The stock has a market cap of $3.13 billion, a PE ratio of -19.97 and a beta of 1.42. The stock has a 50-day moving average price of $32.96 and a 200 day moving average price of $36.29. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $26.81 and a 52 week high of $74.77. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.16.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ARWR shares. SVB Leerink lifted their price target on Arrowhead Pharmaceuticals from $32.00 to $33.00 and gave the stock a “market perform” rating in a research note on Thursday, November 10th. The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, August 8th. StockNews.com started coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Chardan Capital lifted their price target on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research note on Friday, August 5th. Finally, Morgan Stanley assumed coverage on Arrowhead Pharmaceuticals in a research note on Friday, September 9th. They set an “equal weight” rating and a $41.00 price target for the company. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.00.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider Martin Javier San sold 19,500 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $29.99, for a total value of $584,805.00. Following the completion of the sale, the insider now owns 91,500 shares in the company, valued at approximately $2,744,085. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is currently owned by company insiders.

About Arrowhead Pharmaceuticals

(Get Rating)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.

Featured Stories

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Rating).

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.